Bli medlem
Bli medlem

Du är här

2015-12-16

Immunicum has received approval to extend the phase I/II-study in liver cancer by up to six patients to be treated with INTUVAX in combination with first-line t

Immunicum AB
Company Announcement

Immunicum has received approval to extend the phase I/II-study in liver cancer
by up to six patients to be treated with INTUVAX in combination with first-line
treatments

Gothenburg, Sweden, 2015-12-16 08:57 CET (GLOBE NEWSWIRE) --

Immunicum AB (publ) announced today that the Swedish Medical Products Agency
and the Ethics Committee has approved that the phase I/II-study in liver cancer
may be extended by up to six patients who will receive INTUVAX in combination
with first-line treatments.

In October 2013, Immunicum started a phase I/II-study (IM-102) in liver cancer.
Patients who previously failed on first-line treatments started treatment with
the cancer immune primer INTUVAX.

An update of the safety and survival data for the ongoing phase I/II trial
(IM-102) with INTUVAX for patients with primary liver cancer (NCT01974661) on
November 25 2015 showed that no serious side effects had been related to the
vaccine. Ten patients with the diagnosis primary hepatocellular carcinoma (HCC)
had been treated. Seven patients had received their three scheduled INTUVAX
doses. Two of the patients suffered a very rapid progression of the disease
already before treatment could start and passed away before the second and
third doses could be given. One patient had received the first of three planned
treatment doses and one patient was expected to start treatment before the
year-end.

All patients had demonstrated tumor progression (tumor growth) after
conventional first-line treatment (local chemoembolization or systemic
treatment with Nexavar) before start of INTUVAX-treatment.

It could be noted that out of the seven patients who received all three planned
INTUVAX doses, five patients exhibited a survival that exceeded the expected
median overall survival. Two of the fully treated patients were still alive and
one of these had not yet passed the expected median overall survival.

Immunicum now announces that it has received approval to extend the phase
I/II-study by inclusion of up to six additional patients who will receive
INTUVAX as first-line treatment in combination with local chemoembolization of
the tumor or with the tyrosine kinase inhibitor Nexavar.

- The good safety profile that INTUVAX has demonstrated in liver cancer now
makes it possible for us to target a patient population that can get INTUVAX at
an earlier stage of the disease, in this case as first-line treatment in
combination with either local chemoembolization or with the tyrosine kinase
inhibitor Nexavar. Thus, the study gives us the opportunity to investigate the
potential synergistic effect of INTUVAX in combination with local
chemoembolization or with systemic treatment with Nexavar. Regarding
combination with local chemoembolization, we expect a synergistic effect with
INTUVAX since local chemoembolization is expected to increased the amount of
dying tumor cells which can subsequently be taken up by locally recruited
dendritic cells. The expected synergy with Nexavar is based on Nexavar’s proven
ability to reduce the immunosuppression inherent in tumors, says Immunicum’s
Chief Scientific Officer, professor Alex Karlsson-Parra.

- By including up to six new patients under the frames of the current study, we
save time and money compared to starting a new safety study on INTUVAX in
combination with first-line therapy in primary liver cancer. The new setup will
give us important information for a possible future phase II/III trial in that
indication, says Immunicum’s CEO Jamal El-Mosleh.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The company’s Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31. www.redeye.se

About INTUVAX

INTUVAX is a cancer immune primer, developed for the treatment of solid tumors.
Its active ingredient is activated white blood cells, so called dendritic
cells, derived from healthy blood donors. Intratumoral injection of these cells
is expected to lead to an inflammatory response which in turn leads to
tumor-specific activation of the patient's cytotoxic T lymphocytes.

About Immunicum AB (publ)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor
diseases. A clinical phase II trial for the Company's most advanced product -
INTUVAX® against kidney cancer - has been initiated. The project portfolio
contains an additional clinical phase I/II study in liver cancer and an
upcoming clinical phase I/II study in gastrointestinal stromal tumors (GIST).

www.immunicum.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.